Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
CMR Surgical kicks off Versius Plus robot’s US commercial launch
(2h)
Philips AI cath lab copilot nets FDA clearance
(4h)
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
(4h)
BioPharma Dive
Merck’s deal for Terns sparks debate over a possible biotech bidding war
(2h)
FDA clears Denali drug in ‘clear step’ for rare disease biotechs
(3h)
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
(4h)
Endpoints News
Biopharma industry pushes back on FDA's 'America First' user fee proposals
(1h)
Recordati says it's received a $12B+ takeover bid
(1h)
UCB picks Georgia for $2B biologics site; AbbVie exec visits China
(2h)
BioSpace
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
(4h)
Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data
(6h)
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod
(7h)
STAT News
Eli Lilly’s deal man, Allogene’s off-the-shelf CAR-T, and Merck’s Terns buy
(1h)
Denali Therapeutics, Corcept Therapeutics win FDA approvals
(2h)
Health influencers talk social media and mental health
(3h)
BioPharma Trend
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(1h)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(21h)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(1d)
Drug Channels
Reflections and Photos from the Drug Channels Leadership Forum 2026
(1d)
NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(2d)
Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand
(6d)
European Biotechnology Magazine
TenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancers
(2h)
Immutrin secures £65m Series A for amyloid-removing heart therapy
(1d)
Organoids: new Roche research centre in Basel will focus on alternative model systems
(1d)
Drug Hunter
February 2026 Patent Highlights
(3h)
ACS Spring 2026 First Time Disclosures
(20h)
TL1A Inhibition in IBD: Deamplifying Biology for Clinical Proof-of-Concept
(2d)
Labiotech.EU
GSK’s two-speed strategy: broad sourcing and selective bets
(1d)
Seven T cell engager companies you should know about
(2d)
The six biotech companies in Portugal you should know about in 2026
(3d)
Bio IT World
The Value of Prediction, and Cost of Success, in Drug Hunting
(13h)
Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies
(1d)
Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
(2d)
GEN News
From Variability to Reliability: A New IgG4 Reference Standard for Consistent Characterization
(5h)
Georgia Chosen as the Location for UCB’s New U.S. Biologics Manufacturing Facility
(6h)
Merck Bolsters Cancer Pipeline with $6.7B Terns Buyout
(22h)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(5d)
Understanding High-Risk Essential Thrombocythemia
(5d)
Son’s Decision to Donate Gave His Father a Second Chance
(5d)
Contract Pharma
Hoth Therapeutics Launches OpenClaw AI for Accelerating Drug Discovery
(1h)
Lifecore Biomedical Inks Two New Agreements with Existing US Customer
(3h)
Piramal Pharma Solutions Procures Korsch X3 Tablet Press at Morpeth Facility
(22h)
Pharma Times
Laigo Bio completes final close of €17m seed financing round
(9h)
Axplora announces expansion as newest part of $60m API investment programme
(1d)
DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
(2d)
Medcity News
Frozen Does Not Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing
(4h)
DPC Is Scaling — The Financing Architecture Isn’t Ready
(5h)
Personalized Rehab Solution: Supporting Patients With Work Responsibilities
(5h)
Chemical & Engineering News
Universities forge a bumpy new path on indirect research costs
(36m)
New drug candidates debut in Atlanta
(37m)
Supercapacitors built from bourbon waste
(2h)
The Pharma Letter
Wave hits the rocks on confounding obesity trial
(1h)
Second positive Phase III results for Kodiak’s Zenkuda
(2h)
Late-stage pipeline to transform progressive pulmonary fibrosis treatment landscape
(2h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1w)
MedWatch
Novo Nordisk chairman: Cost-cutting was the most challenging decision in 2025
(4h)
Gubra re-elects board of directors
(4h)
Lundbeck Foundation reshuffles its board of directors
(4h)
In The Pipeline
Fentanyl's Membrane Behavior
(22h)
Set Phasers to "Kill". No, Not Those Phasers.
(1d)
AI-Predicting Compound Affinity. We Aren't There Yet.
(2d)
Pharmaphorum
Wave's stock wavers on obesity drug data
(1h)
AI predicts liver cancer risk with "high accuracy"
(6h)
Corcept gets FDA OK for first-in-class ovarian cancer drug
(8h)
Drug Discovery Weekly
Global collaboration aims to create safer cancer therapeutics
(4h)
DDW Highlights: 26 March 2026
(7h)
Obesity could be treated without suppressing appetite
(8h)
HIT Consultant
Beyond the AI Arms Race: Why Collaborative Intelligence Is the Only Path Forward for Utilization Management
(1d)
The RCM Trap: Why Cityblock Health is Pivoting AI Investment Toward Medicaid Care
(1d)
The C-Suite Squeeze: Why Hospital IT Budgets Are Shrinking While AI Spending Soars
(2d)
Insights: Pink Sheet
Quotable: Top Experts On Policy Hot Topics
(4h)
Iran War: Fuel Woes Exacerbate Fragility Of Europe’s Medicines Distribution System
(5h)
India Tightens Oversight Of GLP-1 Supply Chain Amid Concerns Of ‘On-Demand’ Availability
(10h)
BioXconomy
How the Digital Medicine Society is advancing clinical trials with digital innovation
(2h)
DiMe CEO on how digital medicine is set to redefine clinical trials
(2h)
Merck bolsters oncology portfolio with $6.7bn acquisition of Terns
(7h)
BioCentury
Science Spotlight: AI studies link preserved thymic function to longer life
(18h)
With $6.7B buy, Merck sees ‘best-in-class’ blockbuster in Terns’ CML therapy
(19h)
Denali approval revives surrogate-endpoint path in neuronal MPS
(19h)
SCRIP
How The Kelun-Merck Pact Shaped Future Of China Dealmaking
(2h)
Anavex Not Giving Up On Alzheimer’s Drug After EU Rejection
(4h)
Executives On The Move: Alphamab Oncology Gets A New CFO From AstraZeneca
(7h)